# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T17:03:07.282301
**Route:** OpenRouter + LaTeX
**Tokens:** 18252 in / 1354 out
**Response SHA256:** 7ca928eac0dea0c9

---

I reviewed the draft for fatal errors in the four specified categories (Data-Design Alignment, Regression Sanity, Completeness, Internal Consistency). I focused only on issues that would embarrass the author or make the submission unsalvageable for journal review.

Findings: No fatal errors detected.

Notes (brief):

- Data-design alignment: Treatment timing (2017–2023) is within the stated data coverage (2015–2023). The author acknowledges that the 2023 cohort has no post-treatment contrast and documents that these 16 states therefore do not contribute to the aggregate ATT—this is explicitly noted in Table 6 and Appendix text. Treatment-definition/timing appears consistent across the main text, tables, and timeline table. The comparison group (5 never-treated + 3 coded as untreated because they adopted in 2024) is consistently documented.

- Regression sanity: I inspected all reported coefficient magnitudes, standard errors, and fit statistics. I found no impossible values (no SEs reported as negative, no "NA"/"NaN"/"Inf", no R² outside [0,1]). Coefficients and SEs are in plausible ranges given the outcomes and aggregate variation. Large SEs where present are discussed and interpreted by the author (e.g., imprecision for small cohorts).

- Completeness: I found no placeholder tokens (NA/TBD/TODO/XXX) in tables that should contain estimates. Sample sizes / N and clustering are reported for regressions and estimators, and standard errors are reported. Figures/tables referenced in the text are present (or explicitly described as omitted where small cell sizes justify omission). The author documents why the 2023 cohort lacks estimated group-time ATTs.

- Internal consistency: Numbers cited in the abstract and text (e.g., aggregate ATT = 2.35, SE ≈ 0.55; RI p = 0.45; cohort ATTs range) match the tables. Treatment timing and sample period are consistently described across sections and the appendix. Exclusions (4 ambiguous states) are consistently reported.

Because I found no issues that meet your definition of a fatal error in the four categories, the paper is ready to proceed to referee review from the perspective of these checks.

ADVISOR VERDICT: PASS